[REVISION HISTORY]

Body image and GLP-1 medication trends in Brazil

Updated 12 times since CLSTR started tracking revisions of this situation.

What changed

2026-08-27 08:15 UTC → 2026-09-23 20:41 UTC · added ~~removed~~

Health experts and regulatory bodies in Brazil ~~are intensifying~~ continue to intensify warnings regarding the use of GLP-1 receptor agonists, such as semaglutide and tirzepatide, for weight loss. While effective for obesity, a systematic review of over 15,000 participants indicates that rapid weight loss via these ‘weight loss pens’ can lead to significant reductions in lean muscle mass. Medical specialists, including the Brazilian Society of Pediatrics (SBP), have issued national alerts regarding unsupervised use among children and ~~adolescents. Potential adverse effects for younger populations include~~ adolescents, citing risks such as growth ~~and development~~ deficits, dehydration, and electrolyte ~~imbalances, acute pancreatitis,~~ imbalances. Recent academic discussions, including at a nutrition event at UNIGRAN, emphasize that these medications must be integrated into a comprehensive strategy involving medical supervision, nutritional guidance, physical activity, and ~~gallbladder issues.~~ mental health support. Experts warn that ~~using these drugs for purely aesthetic purposes may~~ improper use or aggressive weight loss goals can trigger ~~eating disorders like anorexia and bulimia, as well as anxiety and depression. The SBP~~ a “rebound effect” or weight cycling. Furthermore, medical professionals are cautioning against focusing solely on scale numbers, noting that rapid reduction can negatively affect body contour, skin quality, and hydration. While the ~~Brazilian Society of Endocrinology and Metabology (SBEM) emphasize~~ Body Mass Index (BMI) remains a common classification tool, experts advocate for an individualized approach that ~~improper use can lead to significant loss of~~ considers genetics, muscle ~~mass~~ structure, and ~~micronutrient deficiencies.~~ liquid retention to achieve well-being rather than strictly aesthetic goals. To ~~combat sarcopenia, endocrinologists~~ mitigate muscle loss, specialists recommend maintaining high protein intake ~~alongside strength training. Specifically, endocrinologist Marcio Mancini suggests a protein intake of 1.2g/kg/day for healthy young individuals~~ and ~~1.5g/kg/day for the elderly or those at risk of sarcopenia~~ strength training, with specific targets suggested by endocrinologists to ~~mitigate the effects of intense appetite suppression and delayed gastric emptying. Recent clinical data has expanded the scope of known risks. A 2024 study published in~~ combat sarcopenia. Clinical ~~Medicine indicated that semaglutide users experienced a 2.6% decrease in hip~~ data also indicates potential risks to bone mineral density ~~and a 2.1% decrease~~ in the hip and lumbar spine density compared to a placebo group over 52 weeks. While these medications offer benefits, such as reduced risks of cardiovascular events and protection against chronic kidney disease, specialists emphasize they are not a substitute for bariatric surgery in severe obesity cases. Regulatory and market shifts continue as Anvisa prohibits unregistered products. during long-term use.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.